Page 26 - Read Online

TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag viral hepatitis related hepatocellular carcinoma. World J Surg Oncol
JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. 2013;11:240.
Incidence of hepatocellular carcinoma and associated risk factors 78. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon
in hepatitis C-related advanced liver disease. Gastroenterology improves outcomes following ablation or resection of hepatocellular
2009;136:138-48. carcinoma. Aliment Pharmacol Ther 2010;32:851-8.
75. Lok AS, Everhart JE, Wright EC, Morgan TR, Di Bisceglie AM, 79. Singal A, Volk ML, Waljee A, Salgi R, Higins P, Rogers MA,
Kim H. Maintenance peginterferon (pegIFN) therapy to prevent Marrero JA. Meta-analysis: surveillance with ultrasound for early-
hepatocellular carcinoma (HCC) in patients (pts) with advanced stage hepatocellular carcinoma in patients with cirrhosis. Aliment
chronic hepatitis C (CHC): extended follow-up results from the
HALT-C Trial. AASLD Abstract; 2010. Pharmacol Ther 2009;30:37-47.
76. Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular 80. Lai CL, Yuen MF. Prevention of hepatitis B virus-related
carcinoma: potential targets, experimental models, and clinical hepatocellular carcinoma with antiviral therapy. Hepatology
challenges. Curr Cancer Drug Targets 2012;12:1129-59. 2013;57:399-408.
77. Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and 81. Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver
systematic review: adjuvant interferon therapy for patients with Int 2015;35:71-7.

Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016 17